Key Points
- Director purchase: Keros director Jean Jacques Bienaime bought 1,000 shares at $11.70 on April 15 for $11,700, boosting his stake to 8,450 shares (a 13.42% increase); the trade was executed under a pre‑arranged Rule 10b5‑1 plan and disclosed on an SEC Form 4.
- Earnings miss: Keros reported a Q loss of ($0.86) per share vs. consensus ($0.49) and revenue of $0.39M vs. $3.66M expected, with revenue down 87.2% year‑over‑year.
- Valuation & sentiment: Shares trade near $11.67 with a $230M market cap and a P/E of 6.41; analysts’ consensus is a "Hold" with an average price target of $21.33, while the stock sits closer to its 12‑month low ($10.41) than its high ($22.55).
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was bought at an average cost of $11.70 per share, for a total transaction of $11,700.00. Following the acquisition, the director owned 8,450 shares of the company's stock, valued at approximately $98,865. This trade represents a 13.42% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Keros Therapeutics Trading Down 0.4%
NASDAQ:KROS opened at $11.67 on Friday. The firm has a market cap of $230.13 million, a P/E ratio of 6.41 and a beta of 0.98. The stock's 50 day simple moving average is $12.98 and its 200-day simple moving average is $16.19. Keros Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $22.55.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.37). The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The company's revenue for the quarter was down 87.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.14) EPS. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.
Institutional Trading of Keros Therapeutics
Large investors have recently bought and sold shares of the company. Financial Management Professionals Inc. acquired a new stake in Keros Therapeutics in the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after acquiring an additional 1,166 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Keros Therapeutics in the third quarter valued at $47,000. Tower Research Capital LLC TRC lifted its position in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics in the third quarter valued at $103,000. Institutional investors and hedge funds own 71.56% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently weighed in on KROS shares. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Keros Therapeutics in a report on Monday, December 29th. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a report on Thursday, March 5th. Wall Street Zen lowered Keros Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. TD Cowen raised Keros Therapeutics to a "hold" rating in a report on Friday, December 19th. Finally, Zacks Research lowered Keros Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, January 1st. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $21.33.
Read Our Latest Analysis on Keros Therapeutics
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
